Symphysis Medical
  • Home
  • News
  • SymPhysis Medical named as Futurescope 2020 One2Watch Finalist

SymPhysis Medical named as Futurescope 2020 One2Watch Finalist

SymPhysis Medical named as Futurescope 2020 One2Watch Finalist

 

In March 2020, SymPhysis Medical were named as finalists in the annual Futurescope One2Watch competition.

FutureScope is Ireland’s leading business innovation event, and the One2Watch competition seeks to find Ireland’s most scalable business idea and award the winning company with a prize worth €10k, including a platform to support its growth

The Futurescope event takes place at the Convention Centre Dublin later in 2020 and explores the implications of emerging technologies, featuring keynotes and multiple panel discussions exploring the challenges and opportunities arising from IoT, MedTech, robotics, 5G, VR/AR, artificial intelligence and more.

With over 120 applications for FutureScope’s One2Watch, a number of factors came into play when deciding the final five spots including, market size, innovation and potential to scale. Not an easy task says judge Heidi Corr, “With the five finalists, we are seeing the application of emerging technologies across multiple business sectors, all of which could achieve global scale. With strong value propositions and a high level of innovation and disruption demonstrated by the finalists, I am very excited to see who will be crowned FutureScope’s One2Watch 2020.”

SymPhysis Medical has developed a patient-centric technology to treat fluid build-up in the body as a result of cancer or chronic disease. Their first drainage technology, called RelEase, will provide patients with unparalleled independence and quality of life when compared to current solutions.

The major changing trends in this therapeutic area are the patients' preference towards minimally invasive procedures and reducing the treatment duration with a catheter-based approach. RelEase has the potential to be far superior to any of the current catheter products on the market in addressing both needs.

One2Watch has been proven as an effective platform for growth with finalists from the last three years raising a combined total of €12 million since getting to the final of the competition at FutureScope.

Supported By

Enterprise Ireland
BioInnovate
Translational Medical Device Lab